Rekvina Labs (526075)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At first glance, this is not a business I can analyze; it is a quote. Rekvina Labs trades at ₹4.50 with a market cap of just ₹3 crore. The latest quarter shows sales of ₹0 crore and net profit of ₹0 crore. A company with no revenue and no earnings cannot have a meaningful P/E; the printed 0.00 is an accounting artifact, not value. Profit growth is -500%, sales growth is 0%, and ROCE is 0.00%. The Piotroski F-Score of 2/9 only confirms what I see: deteriorating fundamentals and weak financial health. The 52-week range of ₹4.50 to ₹46.65 means the stock has fallen over 90%, but a falling price is not automatically a bargain. Graham taught us to quantify margin of safety; here, book value is N/A, debt/equity is N/A, and even promoter holding is N/A. I cannot calculate a price-to-book cushion or assess who is in charge. The 324% ROE looks spectacular, but no equity base is reported, so it is likely a distortion from a very small or negative equity, not operating excellence. There is no dividend yield to reward patience. In Buffett's terms, there is no moat, no identifiable earnings power, no predictable cash flow. It could be a shell, a speculative trading counter, or a recovery story that lacks any disclosed evidence. If something real emerges—revenue, positive earnings, a clean balance sheet—I will reconsider. Until then, this is a pass. In the world of value investing, 'too hard' is an acceptable answer. The numbers do not propose a valuation; they propose a mystery. I would rather miss the gain than risk my capital on an undeclared position.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer